Pembrolizumab is a humanized monoclonal antibody (IgG4/kappa isotype) which binds to de PD-1 receptor and blocks its interactions with ligands PD-L1 and PD-L2, potentiating anti-tumor responses. Here, CD274 is linked to neoplasm.